Engflag

Apo-Ramipril

Quick links to important sections

Apo-Ramipril

Apo-Ramipril_EN

Method of action: Ace Inhibiting, Agents Acting In The Renin-Angiotensin System, Antihypertensive, Cardioprotective, Hypotensive

Treatment option: Coronary Artery Bypass Graft, Heart Disease, Hypertension, Diabetic Kidney Disease, Peripheral Arterial Disease, Cerebrovascular Accident, Coronary Heart Disease, Smoking, Nephropathy, Diabetes Mellitus

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apo-Ramipril

Property Description
Active ingredient Ramipril
Form Oral Tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common use Reduction of high blood pressure
Origin Synthetic Compound

Apo-Ramipril is a synthetic, prescription-only medication classified as a cardiovascular agent. Its primary active component is Ramipril, which is supplied as an oral tablet. As a generic preparation, Apo-Ramipril contains the same active ingredient as the original brand-name product, providing the same essential pharmaceutical function for managing blood pressure and fluid balance.

What Type of Medicine is Apo-Ramipril?

Apo-Ramipril belongs to the pharmacological class of Angiotensin-Converting Enzyme (ACE) inhibitors, a group of agents clinically recognized for their role in managing systemic blood pressure. The drug achieves its general purpose by acting on the Renin-Angiotensin-Aldosterone System (RAAS), a crucial mechanism that controls blood vessel constriction. Ramipril works by inhibiting the ACE enzyme, thereby interrupting the formation of the powerful pressure-raising chemical known as Angiotensin II. This class works to achieve sustained pressure reduction, which is its primary therapeutic goal.

Ramipril: Composition, Form, and General Purpose

The core component in this medication is Ramipril, which is functionally classified as a prodrug. This means Ramipril is chemically inactive when ingested and must be metabolized into its fully potent active form, Ramiprilat. Once converted to Ramiprilat, the substance exhibits sustained inhibition of the ACE enzyme. This chemical property ensures systemic action after oral administration. Apo-Ramipril is supplied in an oral dosage form, specifically a tablet, and its overarching general purpose is to facilitate a controlled and predictable reduction in blood pressure, supporting the cardiovascular system by alleviating excessive vascular resistance.

What side effects are possible with Apo-Ramipril?

Official Side Effects and Safety Characteristics

The safety profile of Apo-Ramipril, consistent with its classification as an Angiotensin-Converting Enzyme (ACE) inhibitor, outlines potential adverse reactions categorized by frequency and the body system affected, as documented in official regulatory sources.

Frequency-Classified Adverse Reactions

Adverse reactions listed in regulatory documents are classified to reflect their likelihood of occurrence:

  • Common (occurring in 1% to 10% of users): Includes headache, dizziness, fatigue, hypotension (low blood pressure), and the class-specific persistent, non-productive dry cough. Gastrointestinal effects like nausea and diarrhea are also common.
  • Uncommon to Rare: Less frequent effects include vertigo, mood changes, muscle cramps, and various skin reactions or rashes. Rare effects include specific hepatic conditions like cholestatic jaundice and rare serious events like pancreatitis.

System-Organ Classes and Serious Reactions

Side effects are officially grouped by the System-Organ Class (SOC) they affect, covering Vascular disorders (hypotension), Respiratory disorders (cough), Renal disorders (impaired renal function, hyperkalemia), and Nervous system disorders (dizziness, headache).

Serious Adverse Reactions are explicitly documented and include potentially life-threatening conditions such as Angioedema (swelling of the face, tongue, or throat) and rare reports of severe Hepatic failure and certain blood dyscrasias. Use of Ramipril is contraindicated during pregnancy due to the risk of fetal toxicity, and in patients with a history of prior ACE inhibitor-related angioedema.

Exposure-Related Safety Patterns

Regulatory information notes that certain effects, particularly hypotension and the potential for impaired renal function, are reported to occur more frequently at the start of treatment or when the dose is increased. Specific safety monitoring is often noted for populations such as older adults and those with existing renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Apo-Ramipril overdose details the potential for severe cardiovascular and renal disturbances. The most likely clinical manifestation of overdose is pronounced hypotension (severely low blood pressure), which may be accompanied by signs such as excessive peripheral vasodilatation and bradycardia (slow heart rate).

Due to the potential for severe health consequences, immediate medical attention is required upon the suspicion of overdose. Life-threatening outcomes documented in regulatory labeling include shock, acute renal failure (kidney failure), and potentially serious electrolyte disturbances. These severe manifestations establish the condition under which urgent medical help must be sought.

Regarding management, the official guidance states that treatment is primarily symptomatic and supportive. Procedures may involve volume expansion (such as administering intravenous fluids) to address prolonged hypotension. The regulatory context confirms that no readily available specific antagonist-antidote is known to exist for Ramipril overdose. Furthermore, regulatory documents state that determining the drug's concentration in the blood has no established role in guiding overdose management.

Therapeutic Uses of Apo-Ramipril

What Apo-Ramipril Treats: Main Uses and Benefits

Apo-Ramipril is primarily used for the long-term management of systemic imbalance related to high blood pressure, but its benefits extend into several critical cardiovascular and renal domains. The medication is commonly applied in addressing conditions like essential hypertension, symptomatic heart failure following a heart attack, diabetic nephropathy, and for reducing the risk of major cardiovascular events such as heart attack and stroke in high-risk patients.

By working to manage the systemic imbalance, this therapy contributes to easing the overall symptom load associated with established cardiovascular risk factors. It plays a role in managing symptoms that may interfere with daily functioning, particularly those related to heart weakness, like fluid retention and easy fatigue.

“The overall benefit contributes to maintaining long-term cardiovascular support, assisting patients with maintaining functional stability during symptomatic periods.”

Quick Fact: Management of Systemic Functional Stress

Apo-Ramipril may be part of symptomatic management when conditions involve periods of heightened physiological stress on the cardiovascular and renal systems, assists with maintaining functional stability and supports the patient during difficult episodes associated with chronic disease.

Regulatory References

  1. NIH DailyMed service

Eligibility and Restrictions for Use

Ramipril eligibility is defined by official regulatory categories that determine who can use the medicine and who must be excluded based on documented risk or lack of established data.

Populations for Whom Use is Contraindicated

Absolute non-eligibility is established for patients with a history of angioedema related to any ACE inhibitor or Angiotensin II Receptor Blocker (ARB). Use is also prohibited during the second and third trimesters of pregnancy, in patients who are hemodynamically unstable, or with severe bilateral renal artery stenosis. The medicine is strictly contraindicated for concurrent use with aliskiren in patients with diabetes or renal impairment, and with sacubitril/valsartan (requiring a 36-hour gap).

Restricted and Age-Related Eligibility

  • Children and Adolescents: Use is not indicated because safety and effectiveness have not been established.
  • Older Adults: Eligible, but often require lower initial doses due to the potential for increased sensitivity.
  • Renal and Hepatic Impairment: Eligibility is conditional and requires close supervision; regulatory documents mandate a maximum daily dose restriction in these populations.
  • Lactation: Use is not recommended in nursing women.

The regulatory profile strictly limits the use of Ramipril based on potential high-risk states and lack of established data. These constraints ensure the medication is used only in adult populations where safety and efficacy are formally documented, excluding those with contraindicating prior events or concurrent therapies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Apo-Ramipril (ramipril) can interact with several medicinal products, requiring careful monitoring or adjustment by a healthcare provider.

Do Not Combine: The combination of ramipril with Sacubitril/Valsartan is strictly contraindicated due to a significantly increased risk of angioedema (severe swelling). A 36-hour waiting period must be observed when switching between these agents. Concomitant use with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe kidney impairment because of the heightened risk of low blood pressure, high potassium, and kidney problems. Ramipril is also contraindicated with certain extracorporeal blood treatments (e.g., specific dialysis membranes).

Interactions to Discuss with Your Doctor:

  • Potassium-raising agents: Potassium supplements, salt substitutes containing potassium, or potassium-sparing diuretics (e.g., spironolactone) can raise potassium levels in the blood, leading to potentially dangerous hyperkalemia.
  • Other blood pressure medicines: Diuretics (water pills) and other antihypertensive agents can amplify the blood-pressure-lowering effect, possibly causing excessive hypotension.
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Including high-dose aspirin or ibuprofen, NSAIDs may reduce the blood-pressure-lowering effect of ramipril and increase the risk of kidney function deterioration.
  • Lithium: Ramipril may increase the concentration and toxicity of lithium in the blood.
  • mTOR inhibitors: Medicines like sirolimus, everolimus, or temsirolimus also increase the risk of angioedema.
  • Gold Compounds: Injectable gold (sodium aurothiomalate) may cause nitritoid reactions (facial flushing, nausea, and low blood pressure) when combined with an ACE inhibitor.

Always inform your doctor or pharmacist of all medicines, supplements, or herbal products you are taking.

Mechanism of Action

Apo-Ramipril is a prodrug that is converted primarily in the liver to its active metabolite, ramiprilat. The pharmacodynamic mechanism centers on ramiprilat's action as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE). ACE is a dipeptidyl carboxypeptidase enzyme found predominantly on the luminal surface of vascular endothelial cells.

Inhibition of this enzyme interrupts the biochemical cascade that converts the inactive decapeptide Angiotensin I into the octapeptide Angiotensin II. The resultant reduction in circulating Angiotensin II levels diminishes the peptide's direct vasoconstrictive effects on arterioles, leading to vasodilation. Furthermore, lower Angiotensin II concentrations decrease the stimulation of aldosterone secretion from the adrenal cortex. The reduced aldosterone activity consequently modulates sodium and fluid reabsorption in the renal tubules. Collectively, these molecular and physiological consequences modulate systemic vascular resistance and plasma volume.

Dosage and Administration Information

How to Use Apo-Ramipril: Administration Guidelines

This information details the instructions for administering Apo-Ramipril (Ramipril), focusing on the procedural structure of its use.

Administration Scope

Instruction Domain Requirement
Route of Administration Oral (by mouth).
Dosing Schedule Individually determined by a healthcare provider. May be taken as a single dose or in two equally divided doses per day.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements Capsules should be swallowed whole. Alternatively, the capsule contents may be opened and sprinkled on a small amount of applesauce (approx. 4 oz) or mixed in 4 oz (120 mL) of water or apple juice; the entire mixture must be consumed.
Age-Group Rules Not recommended for use in children and adolescents below 18 years of age as safety and efficacy have not been established.
Missed-Dose Rules If a dose is missed, take it as soon as you remember, unless it is almost time for your next scheduled dose. If so, skip the missed dose and take the next one at the usual time. Do not take a double dose.
Special Conditions The medicine should be taken at approximately the same time each day to maintain regular blood levels.

Resulting Procedural Structure

The administration of Apo-Ramipril follows a structured approach, starting with the determination of an individualized dose that is subject to adjustment (titration) by a healthcare professional. The core procedural steps require the patient to maintain a consistent daily oral intake either by swallowing the capsule whole or by consuming the contents mixed in a specific medium (water, apple juice, or applesauce), ensuring the entire mixture is taken. The protocol also addresses non-routine events by instructing against taking a double dose to cover a missed one, supporting dosing continuity and safety. This structured application is essential for the standardized use of the drug.

Recent Clinical Evidence

Apo-Ramipril: Recent Clinical Evidence

Evaluation of Angiotensin-Converting Enzyme (ACE) Inhibition

Research has explored the effects of Ramipril (marketed as Apo-Ramipril, among others) in managing hypertension (high blood pressure) and heart failure. Studies investigated the compound's application in trial subjects who had essential hypertension or established cardiovascular risk factors.

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor. Research has focused on how ACE inhibition may be associated with measured changes in blood pressure and vascular health. This mechanism is primarily studied for its potential role in regulating the body’s renin-angiotensin-aldosterone system (RAAS).

Key Clinical Findings

Clinical trials evaluated whether use of Ramipril was associated with measured changes in blood pressure parameters over long-term observation periods. The primary outcomes measured often included assessments of systolic and diastolic blood pressure levels, as well as patient-reported cardiovascular events. Findings related to the primary endpoints were observed within the study populations, supporting its use in certain patient cohorts.

Comparative studies have also been conducted to assess Ramipril against placebo or other classes of antihypertensive medications. These comparisons focused on whether the use of Ramipril was associated with a statistically significant difference in measured cardiovascular outcomes, such as rates of heart attack, stroke, or mortality, in high-risk patients. The results from these trials are used to establish the range of effects observed in different study groups.

Dosage and Observation Research

Research reviewed the effects of established dosage levels across various study populations, including individuals with and without existing kidney impairment. Research included analyses that tracked the incidence of reported adverse events across the study population to establish the observed safety profile during the research period.

How should Apo-Ramipril be stored and disposed of?

Storage and Disposal of Apo-Ramipril

Apo-Ramipril (Ramipril) must be stored and handled according to regulatory requirements to maintain its stability and effectiveness.

Official Storage Conditions

The medicine should be stored at controlled room temperature, typically 68 F to 77 F (20 C to 25 C). It is mandatory to keep it out of the sight and reach of children.

Storage Requirement Rule
Temperature Do not freeze; protect from excess heat
Container Keep in the original container, tightly closed
Environment Protect from moisture

Disposal Instructions

Unused or expired Apo-Ramipril must be disposed of following local regulations. The preferred method is using a drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance and placed in a sealed bag for household trash; it should generally not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagAustralia

flagCanada

flagCzech Republic

flagHong Kong

flagLebanon

Equivalent of Apo-Ramipril found in:

A-Z Index: